6
Oct
2026

Adamed Pharma S.A.

Exhibitor at CPHI Milan 2026 stand 16A18, Finished Dosage & Formulation
About Us

Adamed Pharma is a pharmaceutical and biotechnological company, founded on the basis of our own scientific advances and a patent portfolio. With a dedicated team of over 2800 employees, Adamed engages in the development, licensing, manufacturing, marketing and distribution of pharmaceuticals and consumer health products into Europe, MENA, Australia and the Pacific region - more than 70 countries globally, the references include the most renown pharma corporations.

Read more Show less
Sales Markets
Show more Show less
Categories
more categories Show less
  • Country/Region:
    Poland
  • On CPHI since:
    2015
  • Certificates:
    2
  • Employees:
    1000 - 4999
Company types
Licensee
Manufacturer/Innovator
Primary activities
Pharmaceutical Company (generic finished products)
Pharmaceutical Company (innovator finished products)
View company profile
Contact info
Show contact info Hide contact info
Event information
CPHI Milan 2026
  • 6 Oct 2026 - 8 Oct 2026
  • Fiera Milano, Italy
  • Visit us at stand 16A18, Finished Dosage & Formulation

Products Featured at CPHI Milan 2026

  • CANDESARTAN + AMLODIPINE + HCTZ

    Product CANDESARTAN + AMLODIPINE + HCTZ

    Treatment of hypertension, particularly in patients requiring multiple drugs to achieve blood pressure control
  • CYTISINE

    Product CYTISINE


    Smoking cessation aid to reduce nicotine withdrawal symptoms and cravings associated with quitting smoking.
  • EZETIMIBE + ROSUVASTATIN

    Product EZETIMIBE + ROSUVASTATIN

    Treatment of hypercholesterolemia to lower total cholesterol and LDL cholesterol levels
  • MINOXIDIL

    Product MINOXIDIL

    5 % foam, Minoxidil, as a vasodilator, increases microcirculation in the hair follicles and stimulates Vascular Endothelial Growth Factor (VEGF), which is possibly responsible for increased capillary permeability and thus a potent metabolic activity in the anagen phase, which:
    •increases the d...
  • RANOLAZINE

    Product RANOLAZINE

    375mg, 500mg, 750mg extended release tablets, Ranolazine is a selective inhibitor of the late inward sodium current. Inhibiting that current leads to reductions in intracellular calcium levels. It is indicated in adults as add-on therapy for the symptomatic treatment of patients with stable angi...

Adamed Pharma S.A. Resources (1)